Preventing Chronic Migraines Has Been Added to the List of Uses for Atogepant.

Published Date: 20 Apr 2023

Qulipta, a medication sold by AbbVie that blocks the calcitonin gene-related peptide receptor, has recently received approval for treating both episodic and chronic migraine. Data from the PROGRESS trial were used to support the FDA's ruling.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot